NeoPharm Says Japan's Nippon Kayaku Co., Ltd. Terminates License Agreement

Published: Sep 14, 2007

Sept 14 (Reuters) - Drug developer NeoPharm Inc. (NEOL.O: Quote, Profile, Research) said Japanese company Nippon Kayaku Co Ltd (4272.T: Quote, Profile, Research) terminated a license agreement to develop NeoPharm's brain cancer drug in Japan, after U.S. health regulators requested for an additional trial.

Back to news